Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
Mounia Beloueche‐Babari(Engineering and Physical Sciences Research Council), Simon P. Robinson(Engineering and Physical Sciences Research Council)
Cited by 23